Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group

Erica C Nakajima; Amber Simpson; Jan Bogaerts; Elisabeth G E de Vries; Richard Do; Elena Garalda; Greg Goldmacher; Paul E Kinahan; Philippe Lambin; Barbara LeStage; Qin Li; Frank Lin; Saskia Litière; Raquel Perez-Lopez; Nicholas Petrick; Lawrence Schwartz; Lesley Seymour; Lalitha Shankar; Scott A Laurie

doi:10.1200/PO.23.00687

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group

Erica C Nakajima, Amber Simpson, Jan Bogaerts, Elisabeth G E de Vries, Richard Do, Elena Garalda, Greg Goldmacher, Paul E Kinahan, Philippe Lambin, Barbara LeStage, Qin Li, Frank Lin, Saskia Litière, Raquel Perez-Lopez, Nicholas Petrick, Lawrence Schwartz, Lesley Seymour, Lalitha Shankar, Scott A Laurie^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

14 Downloads (Pure)

Abstract

Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials.

Original language	English
Article number	e2300687
Journal	JCO Precision Oncology
Volume	8
DOIs	https://doi.org/10.1200/PO.23.00687
Publication status	Published - 1 Apr 2024

Keywords

Humans
Precision Medicine/methods
Response Evaluation Criteria in Solid Tumors
Radiomics
Medical Oncology
Neoplasms/diagnostic imaging drug therapy

Access to Document

10.1200/PO.23.00687

Full TextFinal published version, 778 KBLicence: Taverne

Fingerprint

Dive into the research topics of 'Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group'. Together they form a unique fingerprint.

Cite this

Nakajima, E. C., Simpson, A., Bogaerts, J., de Vries, E. G. E., Do, R., Garalda, E., Goldmacher, G., Kinahan, P. E., Lambin, P., LeStage, B., Li, Q., Lin, F., Litière, S., Perez-Lopez, R., Petrick, N., Schwartz, L., Seymour, L., Shankar, L., & Laurie, S. A. (2024). Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group. JCO Precision Oncology, 8, Article e2300687. https://doi.org/10.1200/PO.23.00687

@article{903c22cc67aa45dab7724a3d6d47c92b,

title = "Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group",

abstract = "Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials.",

keywords = "Humans, Precision Medicine/methods, Response Evaluation Criteria in Solid Tumors, Radiomics, Medical Oncology, Neoplasms/diagnostic imaging drug therapy",

author = "Nakajima, {Erica C} and Amber Simpson and Jan Bogaerts and {de Vries}, {Elisabeth G E} and Richard Do and Elena Garalda and Greg Goldmacher and Kinahan, {Paul E} and Philippe Lambin and Barbara LeStage and Qin Li and Frank Lin and Saskia Liti{\`e}re and Raquel Perez-Lopez and Nicholas Petrick and Lawrence Schwartz and Lesley Seymour and Lalitha Shankar and Laurie, {Scott A}",

year = "2024",

month = apr,

day = "1",

doi = "10.1200/PO.23.00687",

language = "English",

volume = "8",

journal = "JCO Precision Oncology",

issn = "2473-4284",

publisher = "American Society of Clinical Oncology",

}

Nakajima, EC, Simpson, A, Bogaerts, J, de Vries, EGE, Do, R, Garalda, E, Goldmacher, G, Kinahan, PE, Lambin, P, LeStage, B, Li, Q, Lin, F, Litière, S, Perez-Lopez, R, Petrick, N, Schwartz, L, Seymour, L, Shankar, L & Laurie, SA 2024, 'Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group', JCO Precision Oncology, vol. 8, e2300687. https://doi.org/10.1200/PO.23.00687

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group. / Nakajima, Erica C; Simpson, Amber; Bogaerts, Jan et al.
In: JCO Precision Oncology, Vol. 8, e2300687, 01.04.2024.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Tumor Size Is Not Everything

T2 - Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group

AU - Nakajima, Erica C

AU - Simpson, Amber

AU - Bogaerts, Jan

AU - de Vries, Elisabeth G E

AU - Do, Richard

AU - Garalda, Elena

AU - Goldmacher, Greg

AU - Kinahan, Paul E

AU - Lambin, Philippe

AU - LeStage, Barbara

AU - Li, Qin

AU - Lin, Frank

AU - Litière, Saskia

AU - Perez-Lopez, Raquel

AU - Petrick, Nicholas

AU - Schwartz, Lawrence

AU - Seymour, Lesley

AU - Shankar, Lalitha

AU - Laurie, Scott A

PY - 2024/4/1

Y1 - 2024/4/1

N2 - Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials.

AB - Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials.

KW - Humans

KW - Precision Medicine/methods

KW - Response Evaluation Criteria in Solid Tumors

KW - Radiomics

KW - Medical Oncology

KW - Neoplasms/diagnostic imaging drug therapy

U2 - 10.1200/PO.23.00687

DO - 10.1200/PO.23.00687

M3 - Article

SN - 2473-4284

VL - 8

JO - JCO Precision Oncology

JF - JCO Precision Oncology

M1 - e2300687

ER -